Strategic Planning Milestone Marks 18 Months of Growth and Momentum

Brisbane, Australia – December 22, 2026 – Eighteen months after launch, Ketim Technologies has completed a comprehensive five-year strategic planning session, marking a significant milestone in the company’s evolution from early-stage concept to funded precision psychiatry venture.

Since inception, Ketim has progressed from self-funded beginnings to securing $1.2 million in funding and reaching a $3.7 million valuation. The team has grown from a single founder to a core group of six, supported by additional advisors and collaborators contributing across research, strategy, and operations.

The recent Strategy Day brought together scientific leaders, directors, and investors to define a structured five-year roadmap focused on clinical validation, regulatory progression, and global commercialisation.

The company’s long-term vision remains clear: advancing precision medicine for mental health by integrating biomarker-driven technologies into screening, prediction, and early intervention — beginning with postpartum depression.

“Our mission is to redefine how mental health is understood and treated,” said Dr. Clarissa Yates. “Bringing together scientific expertise, translational strategy, and aligned leadership allows us to move from discovery to real-world impact.”

The session reinforced Ketim’s commitment to building scalable infrastructure while maintaining its founding purpose — transforming maternal mental health through objective, biology-driven diagnostics.

With foundational support from early backers including AngelLoop, and a growing leadership team, Ketim enters its next phase focused on validation, growth, and global impact.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au